Abbott (ABT) Q4 2025 earnings review
Medical Devices Carry the Load as Nutrition Stumbles
Abbott delivered a mixed Q4. While Adjusted EPS of $1.50 (+12% YoY) met targets, top-line momentum hit a wall. Organic sales growth (excluding COVID tests) decelerated sharply to +3.8%, nearly half the ~7-8% run rate seen in the first three quarters. The culprit was a sudden 9.1% organic collapse in Nutrition and continued weakness in Diagnostics. The investment thesis rests entirely on Medical Devices (+10.4% organic) and the projected recovery in 2026, where guidance implies a bounce back to 6.5-7.5% organic growth.
🐂 Bull Case
Despite a slight sequential cooling, Medical Devices grew 10.4% organic, driven by Electrophysiology (+12.5%) and Diabetes Care (+12.2%). New approvals (Volt PFA, TactiFlex) set the stage for continued double-digit growth.
Gross Margin adjusted expanded to 57.1% (up ~100bps YoY) in Q1-Q3 trends, and despite the revenue miss in Q4, Adjusted EPS grew 12%, showing strong expense discipline.
🐻 Bear Case
Nutrition sales fell 9.1% organically. Management cited 'new strategic price actions,' suggesting a potential price war or demand destruction that may take quarters to resolve.
Diabetes Care growth slowed to 12.2% organic in Q4, down from 17-20% in prior quarters. With competitive pressure intensifying, the 'beat and raise' cadence from FreeStyle Libre may be normalizing.
⚖️ Verdict: ⚪
Neutral. The EPS growth is solid, but the revenue quality in Q4 was poor. The sudden drop in Nutrition and deceleration in Diabetes require explanation before buying the 2026 recovery guidance.
Key Themes
Nutrition Segment Breakdown
Nutrition turned from a stable contributor to a major drag, plummeting 8.9% reported and 9.1% organically. The U.S. market was hit hardest, down 13.2%. Management attributes this to 'strategic price actions targeted to increase volume,' implying they were forced to cut prices to defend market share, yet volumes still declined in the immediate term.
Electrophysiology & Heart Failure Strength
The cardiovascular portfolio remains robust. Electrophysiology grew 12.5% organic, accelerating slightly from Q3 trends. Recent approvals for the Volt PFA System (Pulsed Field Ablation) in the U.S. position Abbott to defend against Boston Scientific and Medtronic in this high-growth category.
Strategic Pivot: Exact Sciences Acquisition
Abbott announced an agreement to acquire Exact Sciences (maker of Cologuard), closing in Q2 2026. This moves Abbott aggressively into cancer diagnostics, diversifying away from the struggling core lab/infectious disease testing market. It signals a shift toward higher-growth diagnostic verticals.
China Diagnostics Drag Persists
Diagnostics sales fell 3.6% organically. Core Laboratory grew 3.6%, but this was offset by headwinds in China (Volume-Based Procurement) and falling COVID revenues ($89M vs $176M prior year). The turnaround in this segment continues to be pushed out.
Emerging Markets Pharma (EPD)
Stable. The Established Pharmaceuticals business grew 7.0% organic, driven by 8.7% growth in Key Emerging Markets. This segment remains a reliable cash generator, compounding at high single digits despite currency volatility.
Other KPIs
Stable/Improving. While not explicitly stated in the text summary, the full-year margin expansion trend and 12% EPS growth despite revenue softness implies strong gross margin performance, likely aided by mix shift toward Medical Devices.
Decelerating. Revenue grew 12.2% organic. While $2B is a milestone, the growth rate has cooled significantly from the ~20% levels seen earlier in 2025 (e.g., Q3 was +17.2%).
Accelerating. U.S. devices grew 10.7% reported, a solid result. However, International devices grew faster at 13.7% reported (10.1% organic), showing the global nature of the demand.
Guidance
Accelerating vs Q4. This guidance implies a significant rebound from the 3.8% organic growth seen in Q4 2025. It suggests management believes the Nutrition issues are temporary or will be lapped quickly.
Stable. The midpoint ($5.675) represents ~10% growth over FY25 ($5.15). This is consistent with Abbott's long-term 'double-digit EPS growth' algorithm, despite the revenue volatility.
Decelerating sequential growth pattern. Q1 is typically softer, but investors will watch this closely to see if the Nutrition drag persists into the start of the year.
Key Questions
Nutrition Margin & Volume Dynamics
Nutrition organic sales dropped 9.1% due to 'new strategic price actions.' Can you quantify how much of this was price vs. volume? Are we engaging in a price war in the U.S. infant formula market, and when does this segment return to growth?
Diabetes Growth Deceleration
Diabetes Care organic growth slowed to 12.2% in Q4 compared to ~17% in Q3 and ~20% in Q1. Is this a function of tougher comps, or are you seeing saturation/competitive impact in the U.S. CGM market?
Exact Sciences Integration
Regarding the Exact Sciences acquisition closing in mid-2026: How does this alter your capital allocation priorities for the remainder of the year? Should we expect a pause in share buybacks?
China Diagnostics Recovery
You previously signaled a recovery in China Core Lab for late 2025. With Diagnostics still shrinking organically (-3.6%), what is the visibility on the China VBP headwinds stabilizing in 2026?